Greenwich Lifesciences IncNASDAQ:GLSI
- LAST PRICE12.9000
- TODAY'S CHANGE (%)-0.0500 (-0.3861%)
- Bid / Lots12.5000/ 5
- Ask / Lots13.6000/ 2
- Open / Previous Close12.7800 / 12.9500
- Day Range
- 52 Week Range
- Volume19,967
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLSI |
|---|---|---|
| 09:32 ET | 176 | 12.78 |
| 10:28 ET | 200 | 12.8479 |
| 10:32 ET | 114 | 12.85 |
| 10:42 ET | 100 | 12.7 |
| 10:44 ET | 409 | 12.69 |
| 10:53 ET | 548 | 12.551 |
| 11:02 ET | 200 | 12.64 |
| 11:04 ET | 100 | 12.54 |
| 11:06 ET | 400 | 12.675 |
| 11:08 ET | 2100 | 12.68 |
| 11:20 ET | 600 | 12.68 |
| 11:26 ET | 150 | 12.68 |
| 11:31 ET | 1000 | 12.68 |
| 11:51 ET | 100 | 12.55 |
| 12:25 ET | 300 | 12.7435 |
| 12:27 ET | 200 | 12.55 |
| 12:30 ET | 900 | 12.553 |
| 12:36 ET | 600 | 12.84 |
| 12:38 ET | 1200 | 12.8499 |
| 12:39 ET | 100 | 12.67 |
| 01:12 ET | 100 | 12.7126 |
| 01:17 ET | 100 | 12.72 |
| 01:28 ET | 100 | 12.72 |
| 01:33 ET | 600 | 12.6901 |
| 02:45 ET | 315 | 12.7234 |
| 03:56 ET | 400 | 12.92 |
| 03:59 ET | 2313 | 12.9 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Greenwich Lifesciences Inc | 170.2M | -16.2x | --- |
Benitec Biopharma Inc | 165.7M | -1.3x | --- |
Achieve Life Sciences Inc | 175.8M | -4.5x | --- |
Atossa Therapeutics Inc | 176.1M | -6.7x | --- |
Galectin Therapeutics Inc | 163.8M | -3.3x | --- |
aTyr Pharma Inc | 159.9M | -2.3x | --- |
Company Information
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.
Contact Information
- Headquarters
- 3992 Bluebonnet Dr, Building 14STAFFORD, TX, United States 77477
- Phone
- 203-434-3290
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- David Mcwilliams
- Chief Executive Officer, Chief Financial Officer, Director
- Snehal Patel
- Vice President - Clinical & Regulatory Affairs
- Jaye Thompson
- Chief Medical Officer, Director
- F. Joseph Daugherty
- Independent Director
- Kenneth Hallock
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $170.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.31 |
EPS | $-0.79 |
Book Value | $0.52 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
